公开(公告)号：US09505772B2

公开(公告)日：2016-11-29

申请号：US14399396

申请日：2013-05-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shizuo Kasai ,  Hideyuki Igawa ,  Masashi Takahashi ,  Asato Kina

IPC: A61K31/50 ,  C07D491/048

CPC classification number: C07D491/048

Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

公开(公告)号：US09108970B2

公开(公告)日：2015-08-18

申请号：US13886032

申请日：2013-05-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasuyoshi Arikawa ,  Benjamin Jones ,  Betty Lam ,  Christopher Smith ,  Masashi Takahashi ,  Qing Dong ,  Victoria Feher ,  Zhe Nie

IPC: C07D471/04 ,  A61K31/437 ,  A61P11/06 ,  A61P35/00 ,  A61P17/06 ,  A61P29/00 ,  A61P11/08 ,  A61P37/02 ,  A61K31/527 ,  A61K45/06 ,  C07D487/10 ,  C07D519/00 ,  C07D487/04 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/437 ,  A61K31/519 ,  A61K31/527 ,  A61K45/06 ,  C07D471/04 ,  C07D487/10 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中G，L1，L2，R1，R2，R3和R4在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，血液恶性肿瘤，上皮癌（即， 癌症）以及其它疾病，疾病和表示SYK抑制的病症。

公开(公告)号：US20150018363A1

公开(公告)日：2015-01-15

申请号：US14371824

申请日：2013-01-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shizuo Kasai ,  Hideyuki Igawa ,  Masashi Takahashi ,  Tsuyoshi Maekawa ,  Keiko Kakegawa ,  Tsuneo Yasuma ,  Asato Kina ,  Jumpei Aida ,  Uttam Khamrai ,  Mrinalkanti Kundu

IPC: C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D405/14

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有黑色素浓缩激素受体拮抗作用的芳香环化合物，可用作预防或治疗肥胖症等的药剂。 本发明涉及由下式表示的化合物或其盐，其中每个符号如本说明书中所定义。

公开(公告)号：US09440987B2

公开(公告)日：2016-09-13

申请号：US14399251

申请日：2013-05-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shizuo Kasai ,  Hideyuki Igawa ,  Masashi Takahashi ,  Asato Kina

IPC: A61P43/00 ,  C07D519/00 ,  C07D491/048 ,  A61P3/04 ,  A61K31/4355

CPC classification number: C07D491/048 ,  C07D519/00

Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

公开(公告)号：US09199963B2

公开(公告)日：2015-12-01

申请号：US14325564

申请日：2014-07-08

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Hideyuki Igawa ,  Masashi Takahashi ,  Keiko Kakegawa ,  Minoru Ikoma ,  Jumpei Aida

IPC: C07D401/00 ,  A61K31/4965 ,  C07D401/04 ,  C07D401/14 ,  C07D409/14 ,  C07D417/14 ,  C07D405/14

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: Provided is a compound having a melanin-concentrating hormone receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of obesity and the like. A compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 提供具有黑色素浓集激素受体拮抗作用的化合物，并且可用作预防或治疗肥胖症等的药剂。 由式（I）表示的化合物或其盐，其中每个符号如说明书中所定义。

公开(公告)号：US20150111894A1

公开(公告)日：2015-04-23

申请号：US14399396

申请日：2013-05-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shizuo Kasai ,  Hideyuki Igawa ,  Masashi Takahashi ,  Asato Kina

IPC: C07D491/048

CPC classification number: C07D491/048

Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有黑色素浓缩激素受体拮抗作用的芳香环化合物，可用作预防或治疗肥胖症等的药剂。 本发明涉及由下式表示的化合物或其盐，其中每个符号如本说明书中所定义。

公开(公告)号：US10968178B2

公开(公告)日：2021-04-06

申请号：US16496530

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshito Terao ,  Masashi Takahashi ,  Ryoma Hara ,  Kousuke Hidaka ,  Hideki Furukawa ,  Takeshi Yamasaki ,  Shizuo Kasai

IPC: C07D209/96 ,  C07D401/12 ,  C07D403/12 ,  C07D471/10 ,  C07D491/052 ,  A61P3/10 ,  A61P9/04

Abstract: The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for—diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like.

公开(公告)号：US09365540B2

公开(公告)日：2016-06-14

申请号：US14371824

申请日：2013-01-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shizuo Kasai ,  Hideyuki Igawa ,  Masashi Takahashi ,  Tsuyoshi Maekawa ,  Keiko Kakegawa ,  Asato Kina ,  Jumpei Aida ,  Uttam Khamrai ,  Mrinalkanti Kundu

IPC: C07D471/04 ,  C07D409/14 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14 ,  C07D401/14 ,  C07D401/04 ,  C07D417/14

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有黑色素浓缩激素受体拮抗作用的芳香环化合物，可用作预防或治疗肥胖症等的药剂。 本发明涉及由下式表示的化合物或其盐，其中每个符号如本说明书中所定义。

公开(公告)号：US20150336964A1

公开(公告)日：2015-11-26

申请号：US14814878

申请日：2015-07-31

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasuyoshi Arikawa ,  Benjamin Jones ,  Betty Lam ,  Christopher Smith ,  Masashi Takahashi ,  Qing Dong ,  Victoria Feher ,  Zhe Nie

IPC: C07D487/04 ,  A61K45/06 ,  A61K31/527 ,  A61K31/437 ,  C07D487/10 ,  A61K31/519 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61K31/437 ,  A61K31/519 ,  A61K31/527 ,  A61K45/06 ,  C07D471/04 ,  C07D487/10 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中G，L1，L2，R1，R2，R3和R4在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，血液恶性肿瘤，上皮癌（即， 癌症）以及其它疾病，疾病和表示SYK抑制的病症。

公开(公告)号：US20180141951A1

公开(公告)日：2018-05-24

申请号：US15681953

申请日：2017-08-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasuyoshi Arikawa ,  Benjamin Jones ,  Betty Lam ,  Masashi Takahashi ,  Christopher Smith ,  Qing Dong ,  Victoria Feher ,  Zhe Nie

IPC: C07D487/04 ,  C07D519/00 ,  C07D487/10 ,  C07D471/04 ,  A61K31/437 ,  A61K31/527 ,  A61K31/519 ,  A61K45/06

CPC classification number: C07D487/04 ,  A61K31/437 ,  A61K31/519 ,  A61K31/527 ,  A61K45/06 ,  C07D471/04 ,  C07D487/10 ,  C07D519/00

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.